AI News, 33 Pharma Companies Using Artificial Intelligence in Drug Discovery artificial intelligence

An AI-Generated Drug?

There were some headlines the other day about the “first AI-discovered drug”, so that should send us to the work in question to see what’s going on.

“It’s like the Big Pharma companies come into a casino, put a million-dollar coin into a slot machine and with some probability like 10% or something, they get a win.”  Instead of gambling to get at the fruit higher up on the tree, Frey built Deep Genomics, a company using artificial intelligence to discover new disease targets as well as the best compounds to drug them.

My problem with it is that everyone has seen slot machines and knows the low probabilities that they will deliver a huge payoff, and using them as a metaphor makes it sound like we in drug research just randomly throw things around until something delivers.

That one-in-ten figure is indeed the success rate for drug candidates going into clinical trials and making it to eventual approval, but that’s our success rate after we’ve put as much thought as possible into possible targets, modes of action, screening cascades, and the drug candidates themselves.

Here’s the paper authored by the Deep Genomics team with the details on what they’ve done in this case: the story is on Wilson’s disease, a rare copper-storage pathology known to be caused by various mutations in the ATP7B gene, which codes for a copper-transporting protein in hepatocytes.

At any rate, it appears from the literature cited in the Deep Genomics paper above that (outside of Spain) perhaps one out of fifty or so Wilson’s patients have this mutation (there is a paper studying several dozen unrelated Spanish patients that found about half of them with this mutation, though, so there are very strong variations in this number).

When you’re developing a rare disease therapy, some big considerations are: (1) is there an actionable target for therapy, (2) what are the chances of developing an agent that hits this target, (3) how many patients are in need of such a therapy, and (4) can these patients be identified (and identified in time to help them)?

If you can’t find the patients, you can’t treat them, so Deep Genomics is going to have to make sure that every new Wilson’s patient gets sequenced (which, to be sure, is increasingly common) and that they know about it and can find the patients they want (which is not common at all).

The problem is that no one gets sequenced for Wilson’s until they’re already showing overt symptoms of the disease, and I would expect any drug that restores functional protein would mainly stop the damage from getting worse.

Since one can already predict a list of potential steric-blocking antisense oligos from such sequences, it is a relatively small step to generate candidates, at least compared to running a small-molecule discovery effort (especially one in this area!) But keep in mind that the development of such an agent is fraught with difficulty –

MarketWatch site logo

Sep 30, 2019 (WiredRelease via COMTEX) -- The latest report on the Worldwide Healthcare Artificial Intelligence (AI) Market Report is the more professional in-depth of this market is providers the newest industry data and industry future trends, allowing you to identify the products and end users driving Revenue growth and profitability, status and forecast, categorizes, market size (value &

Diagnostic Centers has witnessing the significant growth during the forecast period due to rising implementation of artificial intelligence technology for collection of data of patient to support decision making in hospital workflow has considerably enhanced outcomes, reduced wait times and costs are some of the factors fueling the market growth.

 Based on geography, Asia Pacific holds the largest market share during the forecast period due to increasing R&D expenditure, developments in pharmaceutical and biotechnology sectors, existence of huge patient pool will generate demand for improved healthcare services and growing disposable income are some of the factors driving the market growth in this region.

Supply chain trends mapping the latest technological advancements.  #Order this report here @  The report provides key statistics on the market status of the Healthcare Artificial Intelligence (AI) manufacturers and is a valuable source of guidance and direction for companies and individuals interested in the industry.Firstly, the report provides a basic overview of the industry including its definition, applications and manufacturing technology.

In this part, the report presents the company profile, product specifications, capacity, production value, and 2013-2018 market shares for each company.  Region wise performance of the Healthcare Artificial Intelligence (AI) industry  This report studies the global Healthcare Artificial Intelligence (AI) market status and forecast, categorizes the global Healthcare Artificial Intelligence (AI) market size (value &

Browse Full RD with TOC of This Report @  This Healthcare Artificial Intelligence (AI) market report holds answers to some important questions like:  What is the size of occupied by the prominent leaders for the forecast period, 2019 to 2023?

We are serving 100+ clients with 10000+ diverse industry reports and our reports are developed to simplify strategic decision making, on the basis of comprehensive and in-depth significant information, established through wide ranging analysis and latest industry trends.

We are striving to provide the best customer friendly services and appropriate business information to accomplish your ideas.  Contact No- +1 347 767 5477 (US)         +44 131 463 4161 (UK)

News Insights

With extraordinary speed, Healx, a start-up using AI to drive the repurposing of drugs for neglected diseases, has progressed a project from inception to having a clinical candidate in phase 2a trials within 18 months.

Increasing collaboration In the past year, one of the most well established AI start-ups, BenevolentAI has announced several partnerships, including with AstraZeneca – to target new treatments for chronic kidney disease (CKD) and idiopathic pulmonary fibrosis (IPF), and with Novartis – to investigate indications and responder groups for oncology assets currently in clinical development.

Many start-ups and big pharma companies alike are making multiple partnerships across different disease areas, allowing for a healthily competitive environment for multiple co-existing AI service providers.

In an unprecedented move, 17 partners (including 10 pharmaceutical companies) have come together to create MELLODDY, a consortium hoping to establish a platform allowing machine learning from multiple sets of proprietary data.

It seems that in the near future, increased data sharing and collaboration will help to push this area of the pharmaceutical industry forwards, possibly even into a core position in the pharmaceutical research pipeline.

Implications for intellectual property Some are heralding the emergence of AI in the pharmaceutical industry as the beginning of a new era of drug discovery, where computers will be able to design drugs from start to finish.

Should AI techniques in pharma become exceptionally well established and, for example, automated repurposing of drugs become commonplace, one could imagine that patent claims directed towards second and further medical uses might find themselves falling below the obviousness threshold for patentability more frequently.

Using Artificial Intelligence to make accurate medical predictions? Meet Owkin (Startup Spotlights)

Hear from Owkin, a healthcare startup based in Paris, France. COO and CFO Anna Bondarenko explains her startups purpose, and how the Launchpad ...

Big Data in Pharma: Sitting on a Wealth of Data - Rita Geraldes Simoes, Boehringer Ingelheim

As far as data is concerned, Pharmaceutical Companies have always been clear-sighted and assertive on what insights to get from it, how, and what to do about ...

Gaurav Parchani, Dozee : How AI is changing Indian healthcare

Artificial intelligence is affecting industries across the world, and nowhere is this more true than in the healthcare. In this video, Gaurav Parchani, co-founder and ...

6 Biotech Stocks to Watch in 2019

Big news could cause these biotech stocks to Biotech's biggest stories this year include trial data and FDA decisions for therapies targeting indications with a ...

The Importance of AI in life sciences

In this video, Shahram Ebadollahi, Head of Data Science and AI at Novartis shares his thoughts on: Why AI matters in life sciences 00:00:12 What made ...

Doc.AI ICO Review - Revolutionizing Healthcare via Blockchain

In this video we go over the White Paper , Tokenomics and the Brochure. We do a deep fundamental dive into the Doc.Ai team and the use case of the token.

Spotlight on ECP’s Cancer Distributed Learning Environment (CANDLE) Project

Rick Stevens is associate lab director at Argonne National Laboratory, professor of computer science at the University of Chicago, and principal investigator for ...

Lecture 33 Target based drug design

Target based drug design.

Our Common Portrait. Associates of Novartis Global Service Center in Prague.

A video promoting Diversity & Inclusion at NGSC Prague supporting to make NGSC Prague an Employer of Choice. Learn more:

Structure Based Virtual Ligand Screening Webinar

This webinar structure-based ligand screening in MolSoft's ICM-Pro desktop modeling software. See for more information. 3:00 Introduction to ..